SCHEMBL4045792

SCHEMBL4045792

Oc1cccc(Nc2ncnc3sc4c(c23)CCCC4)c1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 6/20 0.76
EGFR P00533 5/20 0.76
FGFR1 P11362 3/20 0.72
MAPK1 P28482 3/20 0.71
MAPT P10636 3/20 0.71
LMNA P02545 2/20 0.71
RAF1 P04049 2/20 0.71
HTT P42858 2/20 0.71
MEN1 O00255 1/20 0.70
POLB P06746 1/20 0.70
HPGD P15428 1/20 0.70
KMT2A Q03164 1/20 0.70
RAB9A P51151 1/20 0.66
MAP2K1 Q02750 1/20 0.64
SMN1; SMN2 Q16637 1/20 0.64
PDGFRB P09619 1/20 0.63
KIT P10721 1/20 0.63
SRC P12931 1/20 0.63
FLT1 P17948 1/20 0.63
FLT4 P35916 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL924123 0.87 MKNK1 (0.77) MKNK1EGFRFGFR1MAPK1MAPT
SCHEMBL923247 0.86 MKNK1 (1.00) MKNK1EGFRFGFR1MAPK1MAPT
SCHEMBL922549 0.86 EGFR (1.00) MKNK1EGFRFGFR1MAPK1MAPT
SCHEMBL4039669 0.85 MAPK1 (0.95) MKNK1EGFRFGFR1MAPK1MAPT
SCHEMBL938262 0.84 FGFR1 (0.64) MKNK1EGFRFGFR1MAPK1MAPT
SCHEMBL4041935 0.83 MKNK1 (1.00) MKNK1EGFRFGFR1MAPK1MAPT
SCHEMBL4040366 0.83 MKNK1 (0.74) MKNK1EGFRFGFR1MAPK1MAPT
SCHEMBL923360 0.83 MKNK1 (0.71) MKNK1EGFRFGFR1MAPK1MAPT
SCHEMBL5629074 0.80 FGFR1 (0.67) MKNK1FGFR1
SCHEMBL924310 0.79 MAPT (0.69) MKNK1EGFRFGFR1MAPK1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009104027-A1 THERAPEUTIC APPLICATION OF TRICICLIC AROMATIC AND SATURATED BENZO(4,5)THIENO-(2,3-D)PYRIMIDINE DERIVATES, AS WELL AS THEIR THERAPEUTICALLY ACCEPTABLE SALTS VICHEM CHEMIE KUTATÓ KFT (HU) 2009-08-27 WO claimed
US-9789111-B2 Casein kinase 1δ (CK 1δ) inhibitors ELECTROPHORETICS LIMITED (GB) 2017-10-17 US disclosed
US-9763947-B2 Casein kinase 1delta (CK1delta) inhibitors ELECTROPHORETICS LIMITED (GB) 2017-09-19 US disclosed
US-9763947-B2 Casein kinase 1delta (CK1delta) inhibitors ELECTROPHORETICS LIMITED (GB) 2017-09-19 US disclosed
US-20160354375-A1 CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES ELECTROPHORETICS LIMITED (GB) 2016-12-08 US disclosed
US-20160058745-A1 CASEIN KINASE 1DELTA (CK 1DELTA) INHIBITORS ELECTROPHORETICS LIMITED (GB) 2016-03-03 US disclosed
US-20160058745-A1 CASEIN KINASE 1DELTA (CK 1DELTA) INHIBITORS ELECTROPHORETICS LIMITED (GB) 2016-03-03 US disclosed
EP-2651404-B1 CASEIN KINASE 1DELTA (CK1DELTA) INHIBITORS ELECTROPHORETICS LTD (GB) 2015-10-14 EP disclosed
US-20150209368-A1 CASEIN KINASE 1DELTA (CK 1DELTA) INHIBITORS ELECTROPHORETICS LIMITED (GB) 2015-07-30 US disclosed
US-20140018540-A1 CASEIN KINASE 1DELTA (CK 1DELTA) INHIBITORS ELECTROPHORETICS LIMITED 2014-01-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140018540-A1 CASEIN KINASE 1DELTA (CK 1DELTA) INHIBITORS CSNK1G1, CSNK1A1, CSNK1D MKNK1 109/4885EGFR 1704/4885FGFR1 1960/4885
US-20150209368-A1 CASEIN KINASE 1DELTA (CK 1DELTA) INHIBITORS CSNK1A1, CSNK1G1, CSNK1D MKNK1 101/4885EGFR 1696/4885FGFR1 1841/4885
US-20160354375-A1 CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES CSNK1G1, CSNK1A1, CSNK1D MKNK1 70/4885EGFR 1834/4885FGFR1 2009/4885
US-20160058745-A1 CASEIN KINASE 1DELTA (CK 1DELTA) INHIBITORS CSNK1A1, CSNK1G1, CSNK1D MKNK1 101/4885EGFR 1696/4885FGFR1 1841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.